Carbonic anhydrases (CAs) 1 are zinc-metalloenzymes that catalyze the reversible interconversion of CO 2 and HCO 3 -(1). Since their discovery, the CAs have been extensively studied due to their important physiological functions in all kingdoms of life. This family of enzymes is broadly composed of three well-studied, structurally distinct (R, , and γ) classes. The R-class is present in vertebrates but is also shown to be present in other organisms. They (and R-CA domains in more complex isoforms) have a molecular weight of ∼29 kDa. There are 14 expressed R-CAs (CA I-XIV) in humans, and the active CAs play roles in respiration, pH homeostasis, fluid production, and other functions as yet to be determined (2) (3) (4) (5) . The R-CAs all share the same overall mixed R/ fold with approximate dimensions of 50 × 40 × 40 Å
3
. The active site is characterized by a conical cavity that is approximately 15 Å deep. The zinc ion is located at the bottom of the conical active-site cavity and is tetrahedrally coordinated by three histidine ligands and a bound hydroxide/water (1) . The active sites between isoforms are nearly identical, other than a few amino acids that line the cavity (6) .
Carbonic anhydrase IX (CA IX) is a unique member of the human R-class of CAs, as it is a membrane-associated glycoprotein, composed of several domains including a short intracellular region, a single transmembrane helix, and an extracellular proteoglycan domain as well as a catalytic CA domain (7) . Under normal conditions, CA IX is commonly expressed in cells that are thought to need to maintain extracellular pH, such as gastric mucosal cells. However, in many cancers it is overexpressed as a result of hypoxia (3) . The regulation of the CA IX gene has been shown to be controlled by hypoxia inducing factor-1 (7) . It has been hypothesized that as tumor growth progresses and becomes insufficient to maintain a supply of oxygen, the cancer cell remodels metabolically, which is partially achieved by the up-regulation of CA IX. Therefore, CA IX is considered to be a marker of tumor hypoxia (8) .
In hypoxic tumors, it is believed that CA IX plays a critical role in cell survival. In tumors there is an observed increase in CO 2 concentration (9, 10) . It is believed that this is not a result of oxidative metabolism but rather a byproduct of an increase in the pentose phosphate pathway. This serves to replenish the supply of NADPH and generate ribose-5-phosphate, necessary for nucleotide and coenzyme production (11) . The surplus of CO 2 is converted to HCO 3 -and a proton by CA IX, creating the significant increase in extracellular proton concentration causing the acidification of the tumor microenvironment. The alteration in proton flux is also believed to affect the activity of ion transporters and channels (5) . Additionally, the acidity may cause the exclusion of weakly basic chemotherapeutic agents rendering traditional therapies less effective (7) . The proteoglycan domain of CA IX has been implicated in the disruption of cell-cell adhesion by breaking the connection of E-cadherin to the cytoskeleton, which may lead to tumor invasion (12) . Several studies have shown that inhibition of CA IX can lead to decreased invasiveness, as well as inducing cell death under hypoxic conditions (3, 8, (13) (14) (15) (16) . These factors, taken together, provide strong evidence to suggest that CA IX might be an attractive drug target for the treatment of cancers.
One significant barrier that needs to be overcome for the development of CA IX inhibitors as effective cancer treatments is to produce a CA IX isoform-specific inhibitor, which has a significantly higher affinity for CA IX than other active CA isoforms. The development of a high-affinity CA IX inhibitor has been hampered due to the lack of an available crystal structure of CA IX. CA IX is a membrane protein and has so far proven itself difficult to express in sufficient soluble and properly folded quantities for crystallization (17, 18) . To overcome these issues, this research reports the expression and structural and kinetics studies of a CA IX active-site mimic. The design of the CA IX mimic is based on a structural-alignment comparison with CA II and is a double mutant of CA II (A65S-N67Q CA II) that imitates the active site of CA IX. This CA IX mimic was expressed and characterized both kinetically and crystallographically, by itself and in complex with several common sulfonamide inhibitors, acetazolamide (AZM), benzolamide (BZM), chlorzolamide (CHL), ethoxzolamide (EZM), and methazolamide (MZM). Preliminary data reveal that the inhibition profiles of the CA IX mimic mirror wild-type CA IX compared to values previously published (17) . In addition, the crystal structures of the CA IX mimic bound to these drugs reflect the kinetics, showing chlorzolamide as the drug with greatest affinity to CA IX, and the CA IX mimic undergoes activesite conformational changes rather than a simple lock and key model of inhibition. Further, this structural information has been evaluated in relationship to inhibition studies and in vitro cytotoxicity assays and shows a correlated structureactivity relationship. To our knowledge, this is the first time a protein mimic has been engineered from a related isozyme for the purpose of drug design. The CA IX mimic presented provides a unique opportunity in developing and assessing CA IX isoform-specific inhibitors, while ongoing studies attempt to obtain the crystal structure of the catalytic domain of CA IX.
MATERIALS AND METHODS
In Silico Design of the CA IX Mimic. All 14 human CA sequences were obtained from the NCBI database and a multiple sequence alignment was performed using Clustal W (19) . A CA IX model was built with the Swiss-Model, using the high resolution CA II crystal structure (PDB accession code: 2ILI) as a template (20, 21) . The molecular graphics programs Coot was used to visualize and analyze the CA IX model (22) .
Enzyme Expression and Purification. The CA IX mimic was made by site-directed mutagenesis using an expression vector containing the CA II coding region (23, 24) . Residues Ala65 and Asn67 were mutated to Ser and Gln, respectively. Site-directed mutagenesis was accomplished using the Quick Change Mutagenesis kit from Stratagene using CA II as a template and the primers (mutations in bold): 5′-CCTCAA-CAATGGTCATTCGTTCCAGGTGGAGTTTGATGAC-3′ and 5′-GTCATCAAACTCCACCTGGAACGAATGAC-CATTGTTGAGG. The DNA sequence was confirmed for the entire coding region for the CA in the expression vector. Expression of the CA IX mimic vector was done by transforming into Escherichia coli BL21(DE3)pLysS, which does not express any endogenous R-CA (25, 26) . The purification of CA IX mimic and CA II was performed on an affinity column of p-amino-methyl-benzenesulfonamide, as described previously in ref (27) . The protein was collected, then buffer exchanged into 50 mM Tris-HCl, pH 7.8, concentrated, and then analyzed for expression and purity using Coomassie-stained SDS-PAGE. The final protein concentration was ∼15 mg mL -1 as calculated by measuring the optical density at 280 nm using a molar absorptivity of 5.5 × 10 4 M -1 cm -1 . Crystallization. Crystals of CA II and CA IX mimic were grown at room temperature using the hanging-drop vapordiffusion method (28) . Crystallization drops were prepared by mixing 7 µL protein (∼15 mg mL -1 in 50 mM Tris-HCl, pH 7.8) with 3 µL precipitant solution (100 mM Tris-HCl, pH 9.0, 1.3 M sodium citrate) and 1 µL of Hampton HR2-410-02 detergent (Hampton Research, Aliso Viejo, CA). The hanging-drops were equilibrated against 1 mL precipitant solution. Crystals appeared within 5 days.
Drug Soaks. The CA inhibitors (acetazolamide (AZM), benzolamide (BZM), chlorzolamide (CHL), ethoxzolamide (EZM), and methazolamide (MZM) see Table 1 ) were solubilized in water, with AZM, CHL, and MZM requiring the addition of 50%, 10%, and 5% of DMSO, respectively. CA IX mimic and CA II crystals were incubated with the inhibitor solutions at 4 mM final concentration for ∼24 h prior to X-ray diffraction data collection. As the density for DMSO is not found in any of the structures presented and the density of the drugs are continuous, it is assumed that the high concentration of DMSO in the drug soaks is not affecting either binding or the chemical composition of these molecules.
Diffraction Data Collection. All the diffraction data for both the CA IX mimic and CA II crystals were collected "in-house" on the RAXIS IV ++ detector using Cu K R wavelength (1.5418 Å). The crystal-to-detector distance was set at a range of 80-100 mm (dependent on the quality of diffraction) and images were collected in one degree oscillation steps with a 300 s exposure time. The data were merged using DENZO and scaled with SCALEPACK using HKL 2000 (29) . Data statistics are listed in Tables 2 and 3 . Structure Determination. All the crystal structures were determined by molecular replacement methods using the previously solved wild-type CA II structure with solvents removed (PDB code 2ILI) (20) . Initially, the structures were refined using the standard refinement protocol of CNS program version 1.1, which included rigid-body, B-factor and energy minimization (30) . Difference Fourier maps provided clear, phase-unbiased electron density for the respective bound inhibitors. The PRODRG server was used to generate topology files for modeling the inhibitor structures during the subsequent refinement process (31) . Once the inhibitors were modeled using the program COOT, refinement continued using the program SHELXL97 (22, 32) . The conjugategradient least-squares model (CGLS) with SHELXL default restraints were used for the protein geometric parameters followed by manual model building with the computergraphics program COOT and the addition of solvent molecules (22, 32) . Refinement of the structures continued until the R cryst and R free converged. The inhibitor-enzyme interactions were determined by observing environmental distances in COOT and the model geometries were analyzed using PROCHECK (22, 33) . The coordinates and structure factors for all nine structures have been submitted to the Protein Data Bank. PDB files, data-refinement, and final model statistics are given in Tables 2 and 3 .
Oxygen-18 Isotope Exchange Kinetic and Inhibition Studies. Inhibition constants (K i values) of all compounds were determined by the measurement of the inhibition of the 18 Oexchange activity between CO 2 and water via mass spectrometry, as reviewed elsewhere (34, 35) . Experiments were carried out at 25°C in solutions buffered at pH 7.4 with 0.1 M HEPES. The concentration of all species of carbonate was 10 mM, 93% HCO 3 -, 7% CO 2 , and 0.1% CO 3 2- . The enzyme concentration was 7.3 nM. Inhibitor concentrations went up to 800 µM and were analyzed by the method of Henderson for tight-binding inhibitors (36) .
Cell Lines and Culture. Human prostate cancer cell line PC-3-Bcl-2 (characterized by marked Bcl-2 overexpression, PTEN deletion, and p53 mutation) was a generous gift from Dr. Timothy McDonnell (The University of Texas M. D. Anderson Cancer Center, Houston, TX). These cells were maintained in Dulbecco's modified Eagle's medium (Mediatech, Inc., Herndon, VA) with 4.5 g/L glucose, 4 mM L-glutamine, 10% fetal bovine serum, 100 units/mL penicillin, 100 µg/mL streptomycin, and 500 µg/mL G418. All cells were incubated at 37°C in a humidified atmosphere of 5% CO 2 in air.
In Vitro Cytotoxicity Assay. The prostate cancer cell line stably transfected to overexpress Bcl-2. PC-3-Bcl-2 cells were seeded in 96-well plates at a density of 2.5 × 10 3 cells per well and treated with drug, control (DMSO only), or mock. The CA inhibitors were dissolved in DMSO and administered at concentrations ranging from 0 to 100 000 nM. After 1-4 days, 100 µL of 1 mg/mL MTT (Sigma-Aldrich, St. Louis, MO) solution was added to appropriate plates and allowed to incubate at 37°C for 2.5 h (37). Each reaction was stopped with lysis buffer (200 mg/mL SDS, 50% N,N-dimethylformamide, pH 4) at room temperature for 1 h, and the optical density was read on a microplate autoreader (Bio-Tek Instruments, Winooski, VT) at 560 nm. Absorbance values were normalized to the values obtained for the mock treated cells to determine survival percentages. Each assay was performed in triplicate, and the mean was calculated from these three assays. Cellular viability was confirmed by means of the crystal violet exclusion test (37) .
Western Blot Analysis. For protein extraction, cells were lysed in lysis buffer [250 mM Tris-HCl (pH 6.8), 2% SDS, and 10% glycerol] and protein inhibitor cocktail (Sigma, St. Louis, MO). A standard protein assay was performed using the DC Protein Assay kit (Bio-Rad, Hercules, CA). Western blot analysis was completed as described previously in ref (38) . Immunoblotting was performed by first incubating the proteins with primary antibodies against CA IX (Novus Biologicals, Littleton, CO) and γ-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA), and then with HRP-conjugated secondary antibody (Bio-Rad). Protein antibody complexes were detected by means of chemiluminescence (Amersham, Arlington Heights, IL).
RESULTS

Sequence and Structural Alignment Comparison.
The multiple-sequence alignment showed the extracellular CA- domain of CA IX (residues 141-390) shared a 39% sequence identity with CA II (residues 1-261). This variation in sequence is approximately the average value of sequence conservation among the human CAs. Superimposition of the three-dimensional Swiss-Model of the catalytic domain of CA IX onto CA II gave an rmsd of the CR atoms of 0.6 Å. Not surprising, most of the amino-acid differences between the two isoforms were on the surface. The three centrally located histidines (residues H94, H96, and H119 in the CA II numbering) that coordinate the zinc ion, the second sphere residues that coordinate the histidines (Q92, S117, and the carbonyl of residue 244), and the amino acids that form the hydrophobic CO 2 binding pocket (residues V121, V143, L198, T199-CH 3 , V207 and W209 in the CA II numbering). were completely conserved (Figure 1 ). Having a 15 Å diameter entrance that tapers into the center of the enzyme, the active-site cavity of CA II can be loosely described as being conical in shape. This cavity is lined with hydrophilic amino acids (residues Y7, N62, H64, A65, N67, T199-Oγ 1 and T200-Oγ 1 in the CA II numbering), and these residues exhibit variation between different isoforms. These amino acids are believed to create a solvent network that influences the rate-limiting proton-transfer step in catalysis. On close inspection of the active-site cavity model of CA IX, it differed from CA II with respect to two of these amino acids, namely, A65S and N67Q (based on CA II residue number- 
b R free was monitored using 5% of the reflection data excluded from refinement. ing) (Figure 1a) . It was hypothesized that these two amino acid differences could cause variations in binding affinity of small molecule inhibitors. Therefore, these point mutations were made to CA II to create the CA IX mimic. It is of note that there is an Ala65 in many CAs; in CA II from mouse, rat, and chicken; in CA VII; and in some CA IV's. There is a Gln67 in CA V; CA VI; CA VII; and in R-CA s -1 and a maximal rate constant for proton transfer from the donor to zinc-bound hydroxide of (8.0 ( 1) × 10 5 (39) . Similarly, the catalytic domain (residues 141-390) of CA IX has been previously cloned and kinetically characterized (17) . The pH profile of k cat /K m for CO 2 hydration was derived from 18 O exchange data and was described by a single ionization with an apparent pK a of 6.3, with a maximal k cat /K m of (5.
. In addition, the pH profile for the proton-transfer-dependent rate constant of CA IX (R H 2 O ) was shown to be bell-shaped at pH 5-8, similar to CA II with R H 2 O corresponding to a ratelimiting proton transfer from a donor of pK a 6.4 to an acceptor (zinc-bound hydroxide) with a pK a of 6.4. This was consistent with the pK a obtained from the pH profile of k cat / K m for CO 2 hydration. The maximal rate constant for proton transfer from the donor to zinc-bound hydroxide was (1. , (pK a ) donor ) 6.8 ( 0.1 and (pK a ) ZnH 2 O ) 5.7 ( 0.1. These data were obtained at 25°C in the absence of buffer using a total concentration of all CO 2 species of 25 mM with the ionic strength maintained at 0.2 M by the addition of sodium sulfate.
Drug Inhibition Studies. Oxygen-18 exchange methods were also used to measure the inhibition of CA II and the CA IX mimic with the inhibitors AZM, BZM, CHL, EZM, and MZM (Table 1 ) and compared to available values for CA IX (17) . The values measured are given in Table 4 . Assessment of the isozyme specificity reveals that AZM, the benchmark CA inhibitor, exhibited a 2-3-fold better binding (Table 1) was performed with both CA II and the CA IX mimic. All the inhibitor-soaked crystals were isomorphous to each other, in the monoclinic space group P2 1 , with mean unit cell dimensions: a ) 42.8 ( 0.1 Å, b ) 41.8 ( 0.1 Å, c ) 72.9 ( 0.1 Å, and ) 104.5 ( 0.1°. The initial electron-densityomit maps showed unambiguously all the inhibitors had bound in the active-site cavity (Figure 2 ). This binding site has been well characterized for CA II and other R-CA isoforms (1). All the structures had expected refinement statistics for structures at 1.5-1.8 Å resolution with comparable R factors and rmsd values to CA II (Tables 3 and  4) . A summary for each of the inhibitor's interactions with CA II and CA IX are listed in Table 5 . Hydrogen bonds and hydrophobic contact distances that change 0.2 Å or less fall within refinement error and are considered to be the same. The unbound CA IX mimic structure had an rmsd value for 249 CR atoms of 0.23 Å compared to CA II (PDB code 2ILI) (20) . There were no significant conformational changes between the unbound CA II and the CA IX mimic, with the exception of residue Ser65 of CA IX mimic exhibited a dual conformation (Figure 1c) . The conformation of Ser65 facing His64 had a 1 angle of -176.3°while the other conformation facing away from His64 was 70.8°. Of additional interest was that the proton-shuttle residue His64 in the CA IX mimic showed a dual conformation similar to that previously described for CA II (35) . This implies that the proton shuttling differences were most likely due to residues outside of the cavity.
All the inhibitor complex structures for both CA II and the CA IX mimic share the same general well characterized sulfonamide binding profile. The N(1) group coordinates to the zinc with a hydrogen bond distance of approximately 2.0 Å and interacts with the nitrogens of His94, His96, and His119 at 3.3-3.6 Å, as well as Thr199 between 2.8-3.0 Å. One oxygen of the sulfonamide group binds to Thr199 at a distance of 3.0-3.2 Å. The other oxygen binds His94 at 3.5 Å, His119 at 3.6 Å, and Zn 2+ at 3.0-3.1 Å. The sulfonamide sulfur binds Zn 2+ with a distance of 3.0 Å. There is a Van der Waals interaction with His94 at a distance of 3.2-3.4 Å as well as numerous weak hydrophobic contacts with residues Trp209, His119, His96, His94, Val121, and Leu198 (listed in Table 5 ).
In AZM, the two nitrogens of the thiadiazole ring form hydrogen bonds with Thr200 at distances of 2.9-3.0 Å and 3.1 Å, respectively. It also forms weak hydrophobic contacts with residues His119, His96, Val143 and Val121 in both CA II and the CA IX mimic (Figure 2b) . The CA II AZM structure contains an additional hydrogen bond with Gln92 with changes to the conformation of the residue and leads to more hydrophobic interactions with Val121 and Phe131, and weakly with Leu198. For the CA IX mimic AZM, there was an additional hydrogen bond with Thr199, which created several weak hydrophobic contacts with Trp209, Gln92, and Phe131. In both structures of BZM, the O(2) of the sulfonamide hydrogen bonds with the nitrogen of Gln92 at a distance of 3.3-3.4 Å, N(3) hydrogen bonds with Thr200 at 2.9-3.1 Å, and more hydrophobic contacts are made with Leu198 and Phe131, as well as several weak hydrophobic interactions (Figure 2c ). The CA II BZM structure has two additional hydrogen bonds, one to Thr200 at 3.2 Å and the other to Gln92 at 3.6 Å. In the CA IX mimic complexed with BZM, there is a 2.9 Å hydrogen bond of the N(2) to Thr200. There are also weak hydrophobic contacts seen with residues His94, Thr200, Phe131 and Val135 (Figure 2d ). EZM has nearly identical interactions with both CA II and CA IX mimic, which consists of the N(2) hydrogen bonding to Thr200 at 3.2-3.4 Å and of hydrophobic contacts including Thr200, Leu198, Trp209, His96, His119, Thr199, Pro201, Pro202, and Val143 (Figure 2g,h) . There are only a few weak Van der Waals interactions different between the two. MZM forms an additional hydrogen bond between O(1) and His119 at a distance of 3.4-3.5 Å and hydrophobic contacts with Thr200, Pro201, and Phe131 in both CA II and CA IX mimic. Most of the difference between CA II and the CA IX mimic bound to MZM are in weak hydrophobic interactions (Figure 2i,j) .
In the case of CHL, both structures show O(2) hydrogen bonding to His119 at 3.6 Å, N(2) binding Thr199 at 3.5-3.6 Å and Thr200 at 3.4-3.5 Å, and N(1) hydrogen bonding to Thr200 at a distance of 3.0-3.1 Å. There are also several Van der Waals contacts with residues Leu198, Trp209, His96, His119, Thr199, and Phe131. The structure of CA II CHL show several new weak hydrophobic interactions (Figure 2e ). However, in the crystal structure of CA IX mimic in complex with CHL, the chlorine hydrogen bonds with Gln92; this pulls residue Gln67 into the active site and fixes Ser65 into one conformation oriented toward the His64 with a X 1 angle of 111.4° (Figure 2f and Figure 3a,b) .
When the drugs are superimposed on one another, the similarities and differences of binding become apparent (Figure 3c-f) . The sulfonamide groups are in nearly superimposible orientations. For the most part, the thiadiazole ring and hydrophobic tail are locked into a planar geometry with two exceptions. In EZM the thiadiazole ring is rotated out slightly, probably due to the additional conjugated ring, and the ethoxy group lies nearly perpendicular to the regular plane. In BZM, the thiadiazole ring 7-3.9, 3.8-4.0), His94 (3.8-4.0,  3.8-4.0, 3.8-4.0), Leu198 (3.6-3.7,  3.7-3.8, 3.8-3.9, 3.9, 3.7-4.0, 3.7-4.0) 
AZM:
N3 HB: Thr200 (2.9-3.0) N2 HB: Thr200 (3.1) wHC: His119 (3.8-3.9, 3.9), His96 (3. is rotated significantly out of the plane and the phenylsulfonyl is rotated nearly 90°as compared to the hydrophobic tails of the AZM, CHL, and MZM and aligning with the ethoxy of EZM.
PC-3-Bcl-2 Western Blot and Cytotoxicity Assay. A Western blot was performed on untreated PC-3-Bcl-2 cells to verify the expression of CA IX in this cancer cell line (Figure 4a) . To determine the effects of carbonic anhydrase inhibitors on cell proliferation and viability, PC-3-Bcl-2 prostate cancer cell lines were treated for 96 h with the carbonic anhydrase inhibitors (at concentrations ranging from 0 to 10 0000 nM), control or mock. Cellular proliferation is depicted at 0.1 mM for all agents (Figure 4b) . AZM, BZM, and EZM even at higher doses had no cytotoxic effects. However, MZM at 0.01 and 0.1 mM demonstrated significant inhibition of proliferation and viability compared to the control (29% and 32% inhibition respectively, p < 0.01). For inhibitor CHL, significant reduction in cellular prolifera- Only compounds CHL and MZM demonstrated reduced proliferation compared to the mock (43% and 68%, respectively). Each assay was performed in triplicate, and the mean for all three experiments was calculated. Crystal violet exclusion test confirmed the above MTT results (i.e., decrease proliferation) were associated with an increase cell death. tion and viability was evident only at 0.1 mM (57% inhibition, p < 0.01). It is important to note that these values are consistent with those previously published for in vitro studies of sulfonamides in cancer cell lines (3, 40) .
DISCUSSION
This work describes the kinetic and structural characterization of a CA IX mimic. Translating the knowledge derived from this mimic to in vitro studies has identified potential drugs for cancers overexpressing CA IX.
The kinetic characterization of the CA IX mimic demonstrates that the two amino acid mutations in CA II to CA IX do imitate CA IX in terms of chemistry at the active-site zinc ion. The values of k cat /K m for the CA IX mimic are similar to those reported for the CA domain of CA IX in Wingo et al. and in Hilvo et al. (17, 18) . However, these values are lower than those reported for the CA domain with the N-terminal proteoglycan domain in Hilvo et al. (18) . The k cat /K m of both the CA IX mimic and CA IX exhibit a 2-fold decrease as compared to CA II which is probably due to a change in hydrophobic properties in the active site caused by the change from the hydrophobic alanine at position 65 to the polar serine residue. In terms of chemistry at His64, however, the kinetic properties of the CA IX mimic are still much like those of CA II. This is likely because there is no significant change in the active-site residues that coordinate the waters in the active-site cavity. This means there is possibly another, non-active-site residue that causes the difference in proton transfer between CA II and CA IX. Further investigation into several theoretical proton shuttling residues identified by molecular dynamics reveal two mutations that might improve the kinetics (41, 42) . The first is Glu69, a Thr in CA IX, and Lys170, which is a Glu. However, despite the difference in proton transfer rates between the CA IX mimic and CA IX, the kinetic profile of the CA II double mutant seems like a good model for inhibition of CA IX in the active-site cavity.
To assess the viability of the CA IX mimic as an analog of wild-type CA IX, the K i values have been compared to CA II with the classic sulfonamides. The CA IX mimic values correspond preferentially to wild-type CA IX, lending credence to use the mimic as a model for CA IX isozyme specificity. However, the CA IX mimic is not perfect, as demonstrated by the slight disparity in K i values between CA IX mimic and wild-type. The differences fall within statistical variation, and given the difficulties in expressing wild-type CA IX, the mimic may provide an opportunity to prescreen possible drugs or as a model for rational drug design.
Recently, a study was published characterizing biochemically the extracellular domains of native CA IX. Among the conclusions of this paper was the identification of both dimeric and monomeric forms of CA IX, in the ratio of 60% to 34%, respectively (18) . Homology modeling of CA IX revealed that the location of the intermolecular disulfide is located on the opposite side of the enzyme, away from the active site. From this information, it was concluded that the dimeric state probably does not affect catalytic activity and, as a result, the monomeric CA IX mimic is still a satisfactory model for CA IX inhibition.
In assuming that the CA IX mimic is an adequate analog, the study reveals valuable information regarding the isozyme specificity of classical sulfonamides. The kinetics and crystal structures reveal an interesting story. In the case of AZM, the K i value is lowered by a factor of 2 in the CA IX mimic, making it a better inhibitor of the mutant than CA II. This could be due to the conformational change of Gln92 in the structure of CA IX mimic as compared to CA II; however, the in vitro studies show AZM has no cytotoxic effect on the PC-3-Bcl-2 cells. As a result, our study indicates that AZM may not be the most effective agent for this purpose.
BZM and MZM show few differences kinetically or structurally, making them less likely to be preferentially effective against the CA IX found in cancer cells. This being said, MZM did show cytotoxic effects against PC-3-Bcl-2 cells, which indicates that it cannot be excluded from the list of possible anticancer therapies. EZM cannot be adequately assessed kinetically due to its subnanomolar K i , and there are few clues structurally as to its isozyme specificity other than increased surface area binding (unpublished data). Until a more sensitive test of kinetics is developed, its potency presents a risk as a cancer treatment due to the high likelihood of inhibiting CA II.
The results of this study suggest that CHL has the most potential for therapeutics. Comparing the structures of CA II versus the CA IX mimic, the chlorine in CHL hydrogen binds to Gln92 in the mimic and not in CA II. This may be the reason for the conformational change of Gln67 and the locking of Ser65 into one position oriented toward His64. Kinetically, the K i value is the lowest in the CA IX mimic, excluding EZM. The increased inhibition is possibly due to the aforementioned Gln67, which is a mutated active-site residue being pulled into a locked down conformation by Gln92 then hydrogen bonding to the other mutant residue Ser65. This binding mode is different from the sulfonamides in CA II, which typically bind in a "lock and key" mechanism, which does not induce conformational changes. Also, CHL is the only structure with a bulky chloride present and halides, such as chlorine, are known to affect the hydrostatics of the surrounding environment. The hydrostatic change of the environment is causing this locked-down effect improving the inhibition and selectivity of CHL. This evidence is supported by the cytotoxicity assay, which shows CHL not only impedes propagation of PC-3-Bcl-2 cells but also induces cell death.
In conclusion, we have developed an effective surrogate of CA IX for use in high-throughput kinetic and structural screenings. The fact that the crystallographic analysis and kinetic studies of the CA IX mimic correlated to the cytotoxicity assay only serves to reinforce this claim. Of the five drugs studied, AZM, MZM, and CHL were identified as potential anticancer drugs, alone or in conjunction with traditional chemotherapy. Further, in vitro and in vivo studies are needed to confirm this assertion, as well as an investigation into the disparity between K i values and growth inhibition curves in vivo. The CA IX mimic also presents a unique opportunity for quick screening of novel CA IX inhibitors.
